Flagship Pioneering merges Cellarity, Etiome and Empress into new AI drug-discovery company Etcelera
What's the story? Flagship Pioneering has combined the platform technologies of Cellarity, Etiome and Empress Therapeutics into a single new company, Etcelera, announced on 29 October 2026. Etcelera launches with continued support from Flagship and other investors to scale its platform and advance drug discovery programmes.
What it does: Etcelera's aim is "causal intelligence" in human biology — working out what actually drives a disease at the molecular level and predicting how a medicine will behave in patients before it ever reaches the clinic. Its unified platform combines high-resolution human cell data (transcriptomics, the read-out of which genes are active), advanced chemoproteomics (how drugs interact with proteins in cells) and large-scale perturbation data (what happens when cells are deliberately altered). The company says this rests on more than 20 years of combined data, including what it calls the industry's largest foundation model trained on 150 million cells and more than 30 AI-powered prediction models.
Pipeline: Etcelera launches with platform-derived programmes in haematology (myelofibrosis and essential thrombocythemia, blood cancers where scar tissue builds up in the bone marrow), metabolism (including partnered programmes in MASH, a common liver disease) and immunology.
Why it matters: Roughly half of drug candidates that reach Phase 2 clinical trials fail because drug developers lack this kind of causal understanding, according to Etcelera chairman Alec Reynolds, a senior partner at Flagship. The new company is led by veteran biotech CEO Ad Rawcliffe, with Flagship founder Noubar Afeyan as co-founder. It is the latest example of Flagship consolidating its often-secretive internal startups to build scale in AI-driven drug discovery.
Read more: Flagship Pioneering, 29 October 2026 · BioPharma Dive, 29 October 2026